American Association for Cancer Research
15357163mct130608-sup-fig5.pdf (142.4 kB)

Supplementary Figure 5 from Disruption of STAT3 by Niclosamide Reverses Radioresistance of Human Lung Cancer

Download (142.4 kB)
journal contribution
posted on 2023-04-03, 14:03 authored by Shuo You, Rui Li, Dongkyoo Park, Maohua Xie, Gabriel L. Sica, Ya Cao, Zhi-Qiang Xiao, Xingming Deng

PDF file - 142K, Niclosamide or in combination with IR inhibits cell proliferation in tumor tissues.



A major challenge affecting the outcomes of patients with lung cancer is the development of acquired radioresistance. However, the mechanisms underlying the development of resistance to therapy are not fully understood. Here, we discovered that ionizing radiation induces phosphorylation of Janus-associated kinase (JAK)-2 and STAT3 in association with increased levels of Bcl2/Bcl-XL in various human lung cancer cells. To uncover new mechanism(s) of radioresistance of lung cancer, we established lung cancer cell model systems with acquired radioresistance. As compared with radiosensitive parental lung cancer cells (i.e., A549, H358, and H157), the JAK2/STAT3/Bcl2/Bcl-XL survival pathway is significantly more activated in acquired radioresistant lung cancer cells (i.e., A549-IRR, H358-IRR, and H157-IRR). Higher levels of STAT3 were found to be accumulated in the nucleus of radioresistant lung cancer cells. Niclosamide, a potent STAT3 inhibitor, can reduce STAT3 nuclear localization in radioresistant lung cancer cells. Intriguingly, either inhibition of STAT3 activity by niclosamide or depletion of STAT3 by RNA interference reverses radioresistance in vitro. Niclosamide alone or in combination with radiation overcame radioresistance in lung cancer xenografts. These findings uncover a novel mechanism of radioresistance and provide a more effective approach to overcome radioresistance by blocking the STAT3/Bcl2/Bcl-XL survival signaling pathway, which may potentially improve lung cancer outcome, especially for those patients who have resistance to radiotherapy. Mol Cancer Ther; 13(3); 606–16. ©2013 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager